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CD4 receptorPlasma membrane is a multifunctional structure that acts as the initial barrier against infection by intracellu-
lar pathogens. The productive HIV-1 infection depends upon the initial interaction of virus and host plasma
membrane. Immune cells such as CD4+ T cells and macrophages contain essential cell surface receptors
and molecules such as CD4, CXCR4, CCR5 and lipid raft components that facilitate HIV-1 entry. From plasma
membrane HIV-1 activates signaling pathways that prepare the grounds for viral replication. Through viral
proteins HIV-1 hijacks host plasma membrane receptors such as Fas, TNFRs and DR4/DR5, which results in
immune evasion and apoptosis both in infected and uninfected bystander cells. These events are hallmark
in HIV-1 pathogenesis that leads towards AIDS. The interplay between HIV-1 and plasma membrane signal-
ing has much to offer in terms of viral ﬁtness and pathogenicity, and a better understanding of this interplay
may lead to development of new therapeutic approaches. This article is part of a Special Issue entitled: Viral
Membrane Proteins — Channels for Cellular Networking.
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HIV-1, the causative agent of AIDS (acquired immunodeﬁciency
syndrome), belongs to the family of Retroviridae [1]. This family has
unique enzyme called reverse transcriptase (RT) that converts viral
RNA into DNA upon viral entry into the cell [2]. The genome of
HIV-1 contains two identical copies of single stranded RNA molecules
which encode nine open reading frames that produce 15 proteins [3].
The three major proteins are Gag, Pol and Env polyproteins. The Gagembrane Proteins — Channels
ersity of Franche-Comte, Hôpital
ex, France. Tel.: +33 381 21 88
bbas),
l rights reserved.polyprotein is cleaved into the structural proteins MA (matrix), CA
(capsid), and NC (nucleocapsid). The gp160 Env protein is cleaved
into a surface (SU) or gp120 glycoprotein and a transmembrane
(TM) gp41 glycoprotein [4]. The three pol proteins PR (protease),
RT (reverse transcriptase) and IN (integrase), provide the essential
enzymatic function for viral life cycle and are present within the
virus particles [4]. HIV-1 encodes six additional proteins; Tat and
Rev, two regulatory proteins, and additional four so called accessory
proteins, Vif, Vpr, Vpu and Nef. Vif, Vpr and Nef are found in the
viral particles whereas Vpu assists in virion assembly [5].
The primary cell surface receptor for HIV-1, the CD4 protein, is a
member of the immunoglobulin superfamily, found on macrophages
and T lymphocytes [6]. The co-receptor for HIV-1 is either CCR5 or
CXCR4 that is expressed on macrophages and T cells [7–9]. CXCR4 is
a α-chemokine receptor speciﬁc for the ligand stromal derived factor
1 (SDF-1 or CXCL 12). CCR5 is a beta chemokine receptor, and like
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receptor. Its ligands are small family of molecules including MIP-1α
(CCL3), MIP-1β (CCL4) and RANTES (CCL5), and variants including
CCL3L1 and CCL4L1 [10,11]. All of these ligands can compete with
HIV-1 and inhibits its entry [12]. Other cell surface molecules can
also participate in HIV-1 binding and entry. Integrin α4β7 can bind
gp120 activating LFA-1 which is involved in viral synapse formation
and cell-to-cell transmission [13]. Furthermore, the host's genetics
can inﬂuence the immune response to HIV-1 infection. The most im-
portant ﬁnding in this regard is the homozygosity for a 32 bp deletion
in CCR5 gene, and homozygous carriers of this mutation are resistant
to R5 strains of HIV-1 infection [14].
Most of HIV-1 infection occurs by sexual exposure, through blood or
frommother to child [15]. Following transmission of the virus, there is a
period of approximately 10 days, known as eclipse phase, before the
RNA become detectable in the plasma. Study of single genome ampliﬁ-
cation and sequencing has shown that 80% of mucosally transmitted
HIV-1 infections are transmitted by single virus [16–18]. At the end of
eclipse phase, HIV-1 and/or HIV-1 infected cells reach the draining
lymph node, where they meet activated CD4+ T cells which are target
for further infection. This process is mediated by dendritic cells (DC)
which bind the virus through DC-SIGN and carry it to activated CD4+
CCR5+ T cells [19]. The virus replicates and spread rapidly throughout
the lymphoid tissues, particularly gut associated lymphoid tissues
(GALT), where memory CD4+ T cells are present in high number
[20]. Approximately, 20% of CD4+ T cells in the GALT are infected
with HIV-1. Up to 60% uninfected CD4+ T cells at this sites die by
activation-induced cell death, resulting in the release of apoptotic mi-
croparticles that can suppress immune function [21]. Therefore, 80% of
CD4+ T cells in GALT are depleted during the ﬁrst 3 weeks of infection
[20,22]. In the absence of antiretroviral drugs the viral load is
maintained constant by a balance between virus turn over and immune
response [23,24]. Moreover, cells are latently infected and are unlikely
to be removed by anti-HIV immune response or even they cannot be
eliminated by HAART [25,26].
Immune activation is associated with extensive apoptosis of T cells,
leading to release of apoptotic microparticles into the blood and in-
creased expression of TNF-related apoptosis inducing ligand (TRAIL),
which kill bystander cells and participates in immune suppression [21].
HIV-1 replicates in infected individuals, with a virion half-life in the plas-
ma of less than 6 h [27]. More than 99% of viral replication occurs in ac-
tivated and productively infected CD4+ T cells in peripheral blood and
lymphoid tissues [28]. The combination of antiretroviral drugs from
different classes in highly active antiretroviral therapy (HAART) could re-
duce the plasma viremia to clinically undetectable level (b40 copies per
ml plasma) within two months in many patients [27,29]. However, the
suppression of viral replication by HAART uncovered the existence of
long-lived HIV reservoirs that occur with extremely low frequency
(0.1–1 cell/106 lymphocytes) [30]. The current antiretroviral regimen
cannot totally purge HIV-1 from these reservoirs. HAART does largely
prevent the establishment of additional infected cells in the reservoirs
and restrain the viral production from established reservoirs [31–33].
Discontinuation of HAART triggers a new systemic infection from these
latent reservoirs [34].
Cells are deﬁned by the physical presence of a lipid bilayer mem-
brane barrier that separates the inside of a cell from extracellular
medium. Extracellular hydrosoluble chemical messengers cannot cross
the cell membrane, and therefore their messages must be transduced
across the membrane. However, lipid soluble messenger can cross cell
membranes and communicate directly with the contents of the cell by
binding to intracellular receptors [35–37]. Thus, the signal transduction
across the plasma membrane is important because of its fundamental
role in cellular communication and regulation of cellular processes [38].
Binding ofHIV-1 to plasmamembrane receptors activatesmultiple intra-
cellular signaling cascades [39]. This signaling requirement is important
for HIV-1 to establish a latent infection of resting CD4+ T cells [39].Plasma membrane mediated signaling events may facilitate viral infec-
tion in various immunological settings in vivo where cellular conditions
need to be primed [40]. It means that HIV-1 exploits plasma membrane
and its receptor signaling network shared among immune system to hi-
jack signaling pathways and to facilitate HIV pathogenesis. This review
describes the role of plasmamembrane signaling during HIV-1 infection.
2. HIV and raft signaling
Rafts, plasma membrane lipid microdomains, are formed by
glycosphingolipids, sphingomyelin and cholesterol packed in the exter-
nal leaﬂet of plasma membrane. Rafts function as biological structures
to control membrane protein–protein interactions [41–43]. Further-
more, rafts also play an important role in the immune response. Despite
their role in immune activation, these host lipid microdomains are
abused to target host cells by different viruses including retroviruses,
measles virus and inﬂuenza. Lipid rafts are exploited by the pathogens
at different stages during infection [44–47]. Lipid rafts participate to
viral entry and exit, as virion assembly areas within the cell, and to
themodulation of cell signaling pathways during the immune response
[48]. Furthermore, speciﬁc positive signal transducer proteins such as
Src family protein tyrosine kinases (Lck, LAT, Fyn) preferentially localize
in lipid rafts [49,50]. A number of other proteins associated with lipid
rafts are GPI (glycosylphosphatidylinositol) anchored proteins (such
as CD59, CD55/DAF, CD14, CD16, CD90/Thy-1), transmembrane pro-
teins, MHC-I and MHC-II molecules, chemokines and other cell surface
receptors (such as CXCR4, CCR5, TCR, BCR, FcRs), and annexin [51,52].
Many pathogens misuse lipid rafts and lipid raft-associated pro-
teins as entry and exit gateways [53]. Additionally to HIV, the inﬂuen-
za and measles viruses among others enter and bud from host cells
via rafts [54,55]. HIV-1 encodes only small set of functional genes.
Host cell proteins and lipids play a critical role in numerous phases
of HIV life cycle. HIV-1 utilizes lipid rafts at various stages of its viral
cycle such as passage through mucosal tissues, infection of host cells
[56], hijacking of cellular signaling pathways for efﬁcient viral replica-
tion and immune evasion [57], exit of host cells [58], or entrance into
the vascular system of the host [59].
HIV-1 attachment and entry into the cell comprise intermolecular
interactions at plasma membrane. First HIV-1 interacts with CD4
which results in conformation change in gp120 to expose chemokine
receptor binding site [60]. Furthermore, the interaction of gp120-CD4
with the chemokine receptor CXCR4 or CCR5 results in gp41 confor-
mational changes initiating membrane fusion and infection process
[61,62]. The HIV entry receptors are preferentially localized in lipid
rafts and lipid rafts drive gp120-gp41, CD4 and chemokine receptor
into a membrane fusion process [63,64], although these ﬁndings are
still discussed [65]. Additionally, glycoshingolipids (Gb3, GM1) of
the host cell that are involved in gp120 interaction are found in mem-
brane microdomains that promote HIV-1 infection [66,67]. Further-
more, c-type lectin DC-SIGN abundantly expressed on dendritic cells
functions as efﬁcient binding of gp120 [19]. DC-SIGN is distributed
in well-organized microdomains on DC, and lipid rafts associated
DC-SIGN molecules act as efﬁcient docking sites for HIV-1 [68–70].
Additionally to virion-associated proteins, soluble HIV-1 proteins
were shown to enter into cells via lipid rafts. HIV-1 Tat is an essential
regulatory protein for viral replication and acts as a transcriptional acti-
vator of the integrated provirus [71]. Beyond, its gene regulatory capac-
ity, soluble Tat was found to enter into the cells in a heparin-dependent
manner, to trafﬁc between cells and is present in a number of cellular
fractions [72,73]. The entrance of Tat was shown to occur through
caveolar endocytosis descending from lipid rafts, not by clatherin coat-
ed pit formation [74]. This entrance route might be helpful for Tat to
escape lysosomal degradation, to move into Golgi apparatus, to be
transported to endoplasmic reticulum (ER) and ﬁnally to be exported
from ER into the cytoplasm of the cell [74]. Drugs targeting cholesterol
or inhibiting glycosphingolipid synthesis were shown to prevent
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for efﬁcient viral entrance [75,76]. HIV-1 virions bind to and enter into
the cell via lipid rafts but also bud out of the cell through lipid rafts
[58]. This selective budding of HIV-1 virions allows the acquisition of
speciﬁc host cells membrane associated proteins and lipids into virions
that are able to deregulate antiviral immune response [77]. Further-
more, HIV Gag and envelope proteins co-localize with lipid rafts on
the surface of infected cells suggesting that assembly and budding
occur at membrane lipids microdomains [58,78]. Moreover, HIV-1 ex-
ploits the lipid trafﬁcking network for efﬁcient replication and for
reaching the plasma membrane [79]. During the budding of HIV from
CD4+ T cells are incorporated the host cell associated lipid localized
molecules such as GPI-anchored proteins CD55 and CD59, MHC-I,
MHC-II, GM1 or FcR [58,80,81]. Additionally during its budding from
macrophages, HIV-1 incorporates the lipid raft associated proteins
such as GPI-anchored protein CD55 and tyrosine phosphatase CD45
[82]. The tyrosine phosphatase CD45, which is speciﬁcally excluded
from T-cell rafts, was found to be associated with rafts in macrophages.
Therefore, rafts on macrophages display different characteristics than
those on T cells [82]. This indicates that HIV-1 budding from macro-
phages would proceed by a different mechanism than via plasmagp120
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Fig. 1. A schematic overview of the signaling pathways activated by HIV-1 through lipid raft
rearrangement. HIV-1 gp120 activates the lipid-associated protein Lck that then activates P
signaling. DAG activates MAPK through PKC signaling. HIV-1 Nef targets TCR-associated lipmembrane. Despite the recent advances in the understanding of HIV-1
pathogenesis, many mechanisms of viral assembly in macrophages
remain to be elucidated [83,84].
Besides viral entry and budding, HIV can use raft signaling to evade
recognition and killing of infected cells [57]. HIV has evolved the various
ways to exploit its host, including the interruption and activation of sig-
naling pathways in its target cell such as T cells, DC and macrophages
[85–88]. HIV-1 gp120 activates MAPKs through ganglioside suggesting
that lipid microdomains serve as an important factor to trigger cell sig-
naling pathways for productive infection [89]. Pyk2 is a protein tyrosine
kinase, involved in the cytoskeleton rearrangement. HIV-1 gp120mod-
ulates the quiescent and activated T cells through MAPKs. The stimula-
tion of primary lymphocyteswith gp120 activates ERK1, ERK2 and Pyk2
in the lipid rafts (Fig. 1) [90]. Additionally, HIV-1 gp120 also activates
MAPKs or focal adhesion tyrosine kinase in primary macrophages. Fur-
thermore, gp120 inhibits B-cell chemotaxis to MCP-5 (CCL-12), MIP-3
(CCL20) and CCL-21 in a HIV coreceptor (CXCR4 and CCR5) and lipid
raft dependent manner via p38 MAPK activation [91].
Nef is an abundant regulatory viral protein that is produced during
early stages of the viral cycle. Nef interacts with and alters host cellu-
lar signaling pathways [92]. Nef contains several key motifs requiredNef
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Fig. 2. Activation of chemokine receptors signaling in HIV-1 infection. HIV-1 gp120 liga-
tion to chemokine receptors (CXCR4) activates G protein and multiple downstream sig-
naling pathways. Gαi/o activates PI3K which stimulates downstream targets such as
Akt, mitogen/extracellular signal regulated kinase (MEK) and extracellular signal regulat-
ed kinases (ERKs). PI3K also triggers the phosphorylation of focal adhesion complex com-
ponent such as proline rich tyrosine kinase (Pyk-2). Cytoskeleton arrangement occurs
through interplay between protein phosphatases and coﬁlin. Gαq/11 activates PLCγ
which hydrolyzes PIP3 into IP3 and DAG which triggers calcium ﬂux and activation of
PKC signaling pathway.
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rich motif (PxxP) of Nef binds to SH3 domains of a variety of
raft-associated molecules including Src family kinases such as Hck,
Fyn, Lck, Lyn, protein kinase C (PKC), MAPK, Pak2, TCRζ and Vav
[94–96]. Furthermore, Nef activates raft-associated molecules that
mediate antiapoptotic effects by phosphorylation of Bad and by
inhibiting apoptosis signaling regulating kinase-1 (ASK-1) [97].
Moreover, Nef interacts with Pak-2 (p21-activated kinase 2) in the
lipid rafts, which results in the activation of transcription factors
such as NF- B and NFAT that leads to T-cell activation [98]. The inter-
action of Nef with Pak2 is mediated by cdc42 and Rac, as Nef activates
these subfamilies of Rho-GTPases via Vav. This mechanism of Nef ac-
tivation of Pak2 by cdc42 and Rac takes place in rafts and depends on
raft integrity (Fig. 1) [99,100]. In Nef-expressing CD4+ T cells, UbcH7
(E2 ubiquitin conjugating enzyme) that is a negative regulator of
T-cell signaling is absent from lipid rafts [101]. Due to the absence
of UbcH7 from rafts, there is accumulation of tyrosine phosphorylated
Vav, leading to increased Cdc42 activity [102]. Nef-induced Pak2 acti-
vation at the plasma membrane could be required to stably form viro-
logical synapses necessary for efﬁcient cell-to-cell transfer of virus
[103,104]. Besides the proline rich motif (PxxP), the myristoylated
form of Nef activates the resting T cells by increasing the level of sig-
naling molecules within raft [105].
3. HIV and chemokine receptor signaling
In 1996, a G-protein coupled receptor designated “fusin”was identi-
ﬁed as the ﬁrst cofactor for HIV-1 entry into CD4-positive cells [6,9,106].
The fusinwas later knownas CXCR4 and its natural ligand is the CXC che-
mokine stromal derived factor 1 (SDF1). Before the discovery of CXCR4, it
was known that CC chemokines such as RANTES, MIP-1α, MIP-1β sup-
press HIV-1 infection [107,108]. Later on, it was conﬁrmed that CCR5 is
also a co-receptor for the entry of HIV-1 [8,109]. Chemokine receptor sig-
naling is associated with diverse signaling pathways that mediate cell
migration, transcriptional activation, cell growth and differentiation
[110,111]. The binding of SDF-1 to CXCR4 activates heterotrimeric
G-proteins (Gα and Gβγ). Although there are several classes of Gα,
such as Gαs, Gαi/o, Gαq/11 and Gα12/13, the CXCR4 molecules are prefer-
entially coupled to Gαi/0 and Gαq/11. Gαq/11 activates phospholipase C-β
(PLCβ), which catalyzes the cleavage of membrane bound phos-
phatidylinositol 4,5 bisphosphate (PIP2) into secondmessengers inositol
triphosphate (IP3) and diacylglycerol (DAG). These signaling pathways
lead to calcium ﬂux and the activation of several PKC isoforms that has
been shown to be important for SDF-1 induced chemotaxis [112,113].
Additionally, SDF-1 binding to CXCR4 activates Gαi/0 which inhibits ade-
nylate cyclase that in turn leads to a reduction in cAMP levels as well as
the activation of phopholipases phosphodiesterase. These signaling
events activate the lipid kinase PI3K via Gαi/0-coupled Src family kinases
as well as PI3Kγ through direct binding of Gβγ to the regulatory subunit
of PI3Kγ [114,115]. SDF-1 binding to CXCR4 also stimulates guanine nu-
cleotide exchange factors (GEFs) such as Tiam1 (T lymphoma invasion
and metastasis 1) and Phosphatidylinositol 3,4,5-triphosphate depen-
dent Rac exchanger-1 (P-Rex1) that is associatedwithRho familyGTPase
such as Rac, Rho, Cdc42 and Ral that modulate cytoskeleton [116–118].
Moreover, SDF-1 also regulates the cytokine and growth factor driven
pathways by activating JAK-STATs signaling which leads to cell pro-
liferation and differentiation [119–121]. Finally, SDF-1 also activates
Cbl/Cbl-b, which functions as an E3 ligase, regulating cell signaling
through ubiquitination [122]. Altogether, SDF-1 and CXCR4 signaling
pathwaymediates chemotactic response for cytoskeleton rearrangement,
cell polarization and migration, transcriptional activation, cell survival
and proliferation.
Binding of HIV to its chemokine receptor (CCR5, CXCR4) has also
been shown to trigger the activation of Pyk2, Erk1/2, PI3K, Akt and
NFAT (Fig. 2) [123–126]. Furthermore, gp120 binding to chemokine
receptor mediates chemotaxis, cytoskeleton rearrangement, and theactivation of coﬁlin (actin depolarization factor) to increase the corti-
cal actin dynamics in resting CD4+ T cells [127]. After the discovery
of HIV-1 coreceptors, the involvement of chemokine signaling in
HIV-1 infection was thoroughly studied [9]. In a series of experiments,
by using PTX and CCR5 mutants, no involvement of chemokine sig-
naling in HIV infection and pathogenesis was shown [128,129].
Later on, a signiﬁcant number of studies have demonstrated that
the chemokine receptor signaling might be important for viral
replication. For example, pretreatment of macrophages or CD4+
T cells with CC-chemokines was found to enhance HIV replication
[130,131]. Similarly, stimulation of CD4+ T cells from HIV infected
subjects with gp120 can induce HIV replication [132]. In addition, the
replication of some HIV-1 isolates in macaque cells were blocked at a
step after entry and reverse transcription but prior to nuclear import
of preintegration complex, but this block could be relieved by the ex-
pression of HIV-1 coreceptors in macaque cells [133]. It was shown
that three to nine amino acid changes in the envelope of SIVmac293
conferred to the virus the ability to replicate 100 to 1000 timesmore ef-
ﬁciently in macrophages [134]. Broad spectrum chemokine inhibitors
(BSCIs) which block chemokine induced chemotaxis in range of leuko-
cytes, irrespective of the chemokine used [135,136], inhibit HIV-1 infec-
tion without blocking gp120/CCR5 interaction [137]. These results
suggest the involvement of coreceptor signaling in post entry steps.
Chemokine receptor signaling plays an important role for the estab-
lishment of latent infection in resting CD4+ T cells [138]. This absolute
requirement of chemokine signaling is even required in resting T cells
exposed to certain cytokines such as IL-2 or IL-7 [139]. In fact, the static
cortical actin in resting CD4+ T cells represents a unique barrier
for viral post entry migration. HIV-1 gp120 utilizes Gαi/o-dependent
signaling from chemokine receptor CXCR4 to activate coﬁlin (actin
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quirement of coreceptor signaling can be observed in resting CD4+ T
cells, since in activated T cells coﬁlin is constitutively active to facilitate
cell cycle driven actin remodeling that renders CXCR4 signaling unnec-
essary [127]. Chemokine signaling also activates rapid actin polymeriza-
tion. This process may be important for capping of CD4 with CCR5 or
CXCR4 and also for efﬁcient synthesis of viral DNA [127,140]. This
early actin polymerization may be involved in assembling large num-
bers of CD4 and CCR5 or CXCR4molecules at plasmamembrane to facil-
itate gp120 binding and viral entry [141]. In addition, CCR5 signaling
has also been shown to trigger unique signaling cascades that activate
kinases and nuclear transcription factors [126,142,143]. It has been
reported that R5 envelopes induce the expression of genes belonging
toMAPK and genes regulating cell cycle [143]. Additionally the R5 enve-
lope also activates NFAT and induces its translocation into the nucleus
that likely enhances viral transcription from LTR promoter [144].
4. HIV and CD4 receptor signaling
The CD4 molecule plays a very important role in the development
and activation of T cells. It increases the afﬁnity of TCR for the peptide
of MHC-II molecules and transduces the signal through associated ty-
rosine kinase p56lck [145–147]. The CD4 molecule consists of an
N-terminal extracellular portion, a transmembrane part and a short
cytoplasmic tail. The extracellular portion of CD4 molecule consists
of four domains (D1–D4) with an Ig-like structure and is involved
in the interaction with class II molecules of the MHC and other ligands
[145,148,149]. The cytoplasmic portion of CD4 is involved in cell sig-
naling and the palmitoylation sequences in the juxtatransmembrane
region of CD4 act as raft targeting motifs [150]. CD4 is required for ef-
ﬁcient recruitment of the TCR to lipid microdomains [151]. Further-
more, CD4 has been shown to be required for MHC clustering and
efﬁcient Lck recruitment to the immunological synapse [152].
Binding of HIV-1 to CD4 is necessary but not sufﬁcient for produc-
tive infection [153]. The interaction of gp120 with CD4 and subse-
quently with CXCR4 or CCR5 is crucial to initiate cell fusion [154].
After binding to CD4, HIV-1 develops conformation change in gp120
that enables it to bind to the chemokine receptors [155,156]. HIV-1
gp120 binding to the CD4 molecule induces rapid tyrosine phosphor-
ylation of Src kinase p56lck that inhibits the binding and chemotaxis of
CD4+ T cells in response to SDF-1α by downregulating CXCR4 [157].
A signiﬁcant reduction in HIV-1 replication has been observed in cells
expressing a truncated cytoplasmic domain of CD4 that resulted from
the inability of the receptor to associate with p56lck and to stimulate
nuclear translocation of NF- B [158]. These results indicate that the
CD4-associated tyrosine kinase Lck is critical in the transduction of
signals that favor T-cell activation. Through its SH2 and SH3 domains
Lck interacts with various downstream targets such as LckBP, PLC-γ,
MAPK, Zap-70 and PI3K [159–162]. The interaction of gp120 to CD4
has been shown to induce the production of IL-6, IL-10, IFN-γ,
TNF-α, and to up-regulate the expression of the Fas antigen
[163–165]. Therefore, the modulation of signaling pathways by bind-
ing of HIV-1 or gp120 to the CD4 receptor may have important conse-
quences for HIV-1 induced pathogenicity [166–169].
The binding of puriﬁed virions of HIV-1 or gp120 to CD4 receptor re-
sults in tyrosine phosphorylation that activates Lck and Raf signaling
pathways through a Ras-independent signaling [170]. Additionally,
the binding of HIV-1 on CD4 molecules activates MEK/ERK signaling
pathways and also stimulates the expression of a number of transcrip-
tion factors such as AP1, NF- B, and C/EBP. The activation of these
signaling pathways is independent of HIV-1 binding to the chemokine
receptors and can be induced in CD4+ T cells by both T-cell tropic
and macrophage-tropic HIV-1 variants [171]. Therefore the increased
expression of inﬂammatory genes by gp120 activation contributes
signiﬁcantly to enhanced HIV-1 replication as well as deregulation of
the immune system.HIV-1 gp120 binds to the CD4 molecule and stimulates LFA-1 in
active conformation that allows binding to ICAM-1 with high afﬁnity
[172]. LFA-1 and ICAM-1 are incorporated into the envelope of virions
budding from activated CD4+ T cells that support productive viral
replication [173,174]. Furthermore, HIV virions exhibiting ICAM-1
are more infectious than ICAM-1-negative virions [175,176]. There-
fore, activation of LFA-1 on target and infected CD4+ T cells enhances
the HIV-1 infectivity and transmission [172]. The ability of gp120 to
activate LFA-1 through CD4 has been further evidenced by increased
sensitivity of quiescent T cells upon interaction with surface bound
gp120 to LtxA. LtxA is a bacterial leukotoxin that preferentially kills
leukocytes bearing the active form of LFA-1 [177]. The binding of
gp120 to CD4 is crucial for LFA-1 activation as the disruption of
gp120 and CD4 interaction prevented the cell contact with ICAM-1
and nulliﬁes the enhanced susceptibility of cells to LtxA [178].
5. Signaling from plasma membrane and HIV pathogenesis
HIV infection results in the progressive decline in CD4+ T cells
and, subsequently, CD8+ T cells. Daily loss of CD4+ T cells has
been estimated between 3.5 × 107 and 2 × 109 cells during HIV in-
fection [179,180]. HIV-1 induces the reduction in immune cells by
various mechanisms. First, the T-cell generation is impaired during
HIV-1 infection which results in fewer healthy T cells being released
into the peripheral bloodstream [181]. Second, HIV induced immune
activation leads to programmed cell death. Third, HIV-1 and its proteins
can induce a more speciﬁc signal to immune cells and directly cause
their apoptosis [182,183]. HIV-1 triggers apoptosis of uninfected
bystander CD4+ and CD8+ T cells [168]. HIV-1 proteins modulate sig-
naling pathways through the plasmamembrane, resulting in T lympho-
cytes depletion (Fig. 3). The lymphocyte apoptosis is highly regulated
and is dependent on the expression of a family of ligands and receptors
such as Fas/FasL, TNF/TNFR, TRAIL/DR4/5. These plasma membrane re-
ceptors are increased during HIV-1 infection and correlated inversely
with CD4+ T-cell number [184–187]. FasL is present on uninfected
macrophages and its expression is enhanced in HIV-1 infected macro-
phages resulting in selective killing of uninfected CD4+ T cells [188].
HIV-1 induces apoptosis through several proteins belonging to the
TNF ligand superfamily, such as TNFα, FasL and TRAIL. Soluble and
membrane-bound Fas and FasL levels are increased in HIV infection.
During HIV-1 infection, the Fas expression is increased in T lympho-
cytes (CD4+ and CD8+) while FasL expression is increased on
monocytes, macrophages and natural killer cells both in peripheral
blood circulation and lymph nodes [189,190]. HIV-1 infected cells
are more susceptible to Fas mediated apoptosis in vitro as compared
to uninfected cells. However, a lot of studies suggest that the infected
cells do not make up the majority of apoptotic cells in vivo [188,191].
Most of apoptotic cell death involves uninfected cells in lymphoid tis-
sues of HIV-infected patients. TNFα is an inﬂammatory cytokine, se-
creted by activated macrophages and lymphocytes, and induces
diverse functions including inﬂammation and apoptosis [192]. TNFα
binds to its receptors TNFR1 and TNFR2 on the plasma membrane
and modulates the host immunity [193]. HIV-1 proteins target TNFR
signaling pathways, modulating gene expression and T-cell apoptosis
which results in immune suppression and formation of viral reser-
voirs during HIV-1 infection [194]. TRAIL is a member of the TNF li-
gand superfamily that mediates apoptosis of CD4+ T cells in HIV-1
infection through its interaction with its death inducing receptors,
DR4 and DR5, on infected cells as well as on bystander cells. During
HIV-1 infection, the expression of TRAIL and DR5 is increased as com-
pared to uninfected cells [195]. Furthermore, HIV-1 infection of mac-
rophages increases the expression of TRAIL, which can then trigger
apoptosis in bystander T cells [196].
The HIV-1 envelope glycoprotein binds to the CD4 receptor and sig-
nals through it without changing its conformation. After binding of
gp120 to CD4 molecule, it activates PKC, and results in decreased FLIP
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optosis [166,197,198]. This CD4-dependent Fas susceptibility requires
CD4 signaling, since deleting the CD4 cytoplasmic tail inhibits the
Fas-mediated apoptotic response [199,200]. Furthermore, mutations
in the binding region of gp120 to CD4 also inhibit CD4+T cell apoptosis
[201]. Moreover, gp120 also binds to CCR5 without ﬁrst binding to the
CD4 molecule, and also makes the CD4+ T cells susceptible to Fas me-
diating killing [202,203]. However, CXCR4 activation by gp120 causes
Fas-independent and caspase-independent CD4+ T cell death
[203,204]. The death signal through CXCR4 is independent of G protein
signaling [205]. Interestingly, the binding of R5 gp120 to CD8+ T cells
does not trigger cell death while binding of X4 gp120 to CXCR4 recep-
tors expressed on CD8+ T cells causes a rapid caspase independent
cell death, despite the equal expression of CCR5 and CXCR4 on the cell
surface [203]. HIV-1 gp120 also induces apoptosis in non-immune
cells as CXCR4 is expressed on a number of cells. Particularly, CXCR4 is
expressed on the cell surface of human neurons. The X4 gp120 binds
and signals through the neuronal CXCR4, and causes a direct caspase in-
dependent cellular apoptosis [206,207]. Furthermore, human hepato-
cytes also express CXCR4 on the cell surface and undergo caspase
independent apoptosis when gp120 binds to hepatocytes via CXCR4
[208]. Thus, the chemokine-mediated apoptosis as a result of HIV enve-
lope gp120 signaling may explain the occurrence of neurologicaldisorders and liver-related diseases during the course of HIV-1 infec-
tion. In addition, HIV-1 gp120 ligation of CXCR4 on macrophages in-
duces the upregulation of membrane-bound TNFα. This up-regulation
of membrane-bound TNFα induces apoptosis through binding to
TNFR2 in CD8+ T cells which favors T-cell depletion [209].
During HIV-1 infection, the extracellular Tat protein is released in
the stromal microenvironment of infected cells that can be efﬁciently
taken up by most of cell types [72]. In uninfected cells, Tat favors the
transmission of both R5 and R4 HIV by inducing the expression of che-
mokine receptors CCR5 and CXCR4 [210,211]. Additionally, exogenous
Tat upregulates the production of TRAIL in macrophages in vitro
[212,213], which may induce TRAIL-dependent apoptosis of bystander
CD4+ T cells in vivo. Moreover, gp120 and Tat can synergize with
FasL expression leading to TCR-induced apoptosis [214]. The HIV-1 ac-
cessory protein Vpu down-regulates the CD4 receptor and allows efﬁ-
cient budding of newly produced virions, and the Vpr protein
increases the susceptibility of Jurkat T cells to Fas-mediated apoptosis
[215]. Finally, Nef is a viral regulatory protein that is expressed abun-
dantly in the early stages of viral replication. Nef-expressing T cells
have been demonstrated to upregulate the Fas and FasL, and to display
increased PD-1 expression, and thereby undergo apoptosis through
both caspase-dependent and -independent mechanisms [216–218].
However, Nef can also prevent the Fas- and TNF-receptor-mediated
1138 W. Abbas, G. Herbein / Biochimica et Biophysica Acta 1838 (2014) 1132–1142apoptosis via interaction with the apoptosis signal regulating kinase-1
(ASK-1) [97].
6. Conclusion
All the important steps of the HIV-1 life cycle i.e. entry, assembly,
budding, induction of signal transduction and subsequent cell activa-
tion are taking place at the plasma membrane. Furthermore, numer-
ous cellular proteins that are essential for HIV-1 propagation are
either concentrated in membrane microdomains or recruited to plas-
ma membrane during the virological synapse. HIV-1 and its proteins
hijack the plasma membrane receptors and the lipid microdomains
to efﬁciently enter into host cells and to optimize viral replication. A
better understanding of the signaling mechanisms resulting from
the interaction of HIV-1 with the plasma membrane holds the key
to unlock part of the mystery of HIV-mediated cell death and patho-
genesis, and will lead to new therapeutic approaches in the future.
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